Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Bruker Daltonics To Webcast Q3 Conference Call On November 4, 2002.


Business Editors

BILLERICA, Mass.--(BUSINESS WIRE)--Oct. 24, 2002

Bruker Daltonics Inc. (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
:BDAL BDAL Battle Doll Angelic Layer (game) ) plans to release its third quarter financial results on Monday, November 4, 2002 after the market closes. The company will then host a live streaming-audio CCBN CCBN Central Coast Bancorp
CCBN Charles County Business Network
 webcast of its operator-assisted earnings conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) that same day. To listen to the webcast, investors can go to www.bdal.com, and then click on the live web broadcast symbol. The on-demand webcast will be available through the company web site for 30 days.

Investors can also listen and participate on the telephone in the US and Canada by calling 888-482-0024 or 617-801-9702 outside the US and Canada. Investors should refer to the Bruker Daltonics Third Quarter Earnings Call. A telephone replay of the conference call will be available for three days, beginning thirty minutes after the completion of the conference. The replay will be available by dialing toll-free 888-286-8010 in the US and Canada or 617-801-6888 outside the US and Canada, and then entering replay pass code 64682.

ABOUT BRUKER DALTONICS

Bruker Daltonics is a leading provider of innovative life science tools based on mass spectrometry. Its substantial investment in research and development allows it to design, manufacture and market a broad array of products intended to meet the rapidly growing needs of a diverse customer base, including pharmaceutical companies, biotechnology companies, proteomics companies, molecular diagnostics companies, academic institutions and government agencies. Bruker Daltonics has diverse technology platforms that integrate automated sample preparation and clean-up, advanced front-end AnchorChip(TM) MALDI MALDI Matrix-Assisted Laser Desorption/Ionization  targets and API source technology with cutting-edge proprietary MALDI-TOF MALDI-TOF Matrix Assisted Laser Desorption Ionization - Time of Flight , MALDI-TOF/TOF, ESI-TOF, ESI-Q-q-TOF, ion trap and FTMS See Fusion FTMS.  mass analyzers, as well as analysis and bioinformatics software. Bruker Daltonics is also a worldwide leader in supplying mass spectrometry-based systems for substance detection and pathogen identification in security, defense and anti-terrorism applications. Further information is available at: www.bdal.com.

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to technological approaches, product development, manufacturing, market acceptance, cost and pricing of Bruker Daltonics' products, dependence on collaborative partners, suppliers, FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute.

When a person begins a civil lawsuit, the person enters into a process called litigation.
 and other risk factors discussed from time to time in Bruker Daltonics' reports or filings with the Securities and Exchange Commission. Bruker Daltonics expressly disclaims any obligation to update the information contained herein.
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Oct 24, 2002
Words:472
Previous Article:Allos Therapeutics, Inc. Announces Third Quarter Conference Call and Webcast.
Next Article:Charlotte Russe Announces Fourth Quarter and Year End Results.



Related Articles
Bruker Daltonics to Webcast Q2 Conference Call on August 8, 2001.
Bruker Daltonics to Webcast Q3 Conference Call on November 5, 2001.
Bruker Daltonics to Webcast Q4 Conference Call On February 22, 2002.
Bruker Daltonics to Webcast Q1 Conference Call on May 6, 2002.
Bruker Daltonics to Webcast Q2 Conference Call on August 8, 2002.
Bruker Daltonics Second Quarter 2002 Product Revenues Up 25%, Operating Earnings Before Restructuring Charge Triple.
Bruker Daltonics Reports Strong Growth in Revenue and Operating Income for the Third Quarter 2002.
Bruker Daltonics Reports First Quarter 2003 Product Revenue of $34.1 Million, an Increase of 19% Before Currency Effects.
Bruker BioSciences Corporation to Release Third Quarter 2003 Financial Results on November 5, 2003.
Bruker BioSciences Corporation to Release Third Quarter Financial Results on November 2, 2005.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles